NEW YORK, Sept. 4, 2013 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML ) announced today that Ivan Bergstein, M.D., Chief Executive Officer, will present at the 15 th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, on Tuesday, September 10 at 10:50 a.m. ET. The Conference will take place at the Millennium Broadway Hotel in New York, NY. A live webcast and 30-day archive of the event can be viewed on the Company's website at www.stemline.com .
About Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Stemline's clinical candidates, SL-401 and SL-701, have demonstrated clinical activity, including durable complete responses (CRs), in Phase 1/2 studies of patients with advanced hematological and brain cancer, respectively. For more information about Stemline Therapeutics, visit www.stemline.com . The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.
Stemline Contact: Mark Jacobson Director, Corporate Development Stemline Therapeutics, Inc. 750 Lexington Avenue Eleventh Floor New York, NY 10022 Tel: 646-502-2307 Email: